



17 September 2020

Sydney, Australia

Notification of Date of 2020 Annual General Meeting

Sydney, 17 September 2020: Nyrada Inc (ASX: NYR) advises that the Company's Annual General Meeting (AGM) will be held on Thursday 19 November 2020 at 10:00 am AEDT.

Further to Listing Rules 3.13.1 and 14.3, nominations for election of directors at the AGM must be received not less than 35 Business Days before the meeting, being no later than Thursday 1 October 2020.

The location of the AGM is subject to COVID-19 restrictions, including regulatory requirements. Further details, including any hybrid or virtual meeting arrangements, will be confirmed closer to the AGM.

Following formalities, Nyrada's Non-Executive Chair, Mr John Moore and CEO, Mr James Bonnar will provide a corporate update on the Company's successful first eleven months since listing on ASX.

In order to receive electronic communications, shareholders are encouraged to contact the share registry, Automic Group, via the details below:

- Visit: www.automicgroup.com.au
- Email: hello@automic.com.au
- Telephone: (Within Australia) 1300 288 664 (Outside Australia) +61 2 9698 5414

About Nyrada Inc

Nyrada is a preclinical stage, drug discovery and development company, specialising in novel small molecule drugs to treat cardiovascular, neurological, and inflammatory/autoimmune diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, USA, and the liability of its stockholders is limited.

-ENDS-

Authorised by Mr John Moore, Non-Executive Chairman, on behalf of the Board.

www.nyrada.com

Investor & Corporate Enquiries:

Prue Kelly
T: 0459 022 445
E: info@nyrada.com

Company Secretary:

David Franks
T: 02 8072 1400
E: David.Franks@automicgroup.com.au

Media Enquiries:

Catherine Strong
Citadel-MAGNUS
T: 02 8234 0111
E: cstrong@citadelmagnus.com